- Home
- ICON vs CMND Comparison
ICON vs CMND Comparison
Compare ICON & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- CMND
- Stock Information
- Founded
- ICON 2023
- CMND 2017
- Country
- ICON Greece
- CMND Canada
- Employees
- ICON N/A
- CMND N/A
- Industry
- ICON
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- CMND Health Care
- Exchange
- ICON Nasdaq
- CMND Nasdaq
- Market Cap
- ICON 4.7M
- CMND 5.3M
- IPO Year
- ICON 2024
- CMND N/A
- Fundamental
- Price
- ICON $2.21
- CMND $1.02
- Analyst Decision
- ICON Strong Buy
- CMND
- Analyst Count
- ICON 1
- CMND 0
- Target Price
- ICON $4.50
- CMND N/A
- AVG Volume (30 Days)
- ICON 37.5K
- CMND 34.4K
- Earning Date
- ICON 09-10-2025
- CMND 09-11-2025
- Dividend Yield
- ICON 426.34%
- CMND N/A
- EPS Growth
- ICON N/A
- CMND N/A
- EPS
- ICON N/A
- CMND N/A
- Revenue
- ICON $6,137,000.00
- CMND N/A
- Revenue This Year
- ICON $94.05
- CMND N/A
- Revenue Next Year
- ICON $18.81
- CMND N/A
- P/E Ratio
- ICON N/A
- CMND N/A
- Revenue Growth
- ICON 25.60
- CMND N/A
- 52 Week Low
- ICON $1.60
- CMND $0.80
- 52 Week High
- ICON $130.80
- CMND $2.18
- Technical
- Relative Strength Index (RSI)
- ICON 51.92
- CMND 50.32
- Support Level
- ICON $1.87
- CMND $0.99
- Resistance Level
- ICON $2.37
- CMND $1.04
- Average True Range (ATR)
- ICON 0.11
- CMND 0.04
- MACD
- ICON 0.04
- CMND -0.00
- Stochastic Oscillator
- ICON 67.00
- CMND 33.33
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.